International Symposium on Hodgkin Lymphoma
Preliminary Program (This Version: September, 2018)

Saturday (27.10.2018)

08:45 – 10:15 Workshops
- Radiotherapy in Salvage (S. Mammitz-Schultze, J. Yahalom)
- Molecular Pathogenesis (M. L. Hansmann, L. Steidl)
- Developing Health Care Environments (A. Hagenbeck, D. Henke)
- Paedron Emission Tomography (M. Dietlein, M. Meignan)

Coffee Break

10:30 – 12:00 Workshops
- Survivorthor (E. van Leeuwen, A. Plate)
- Immunotherapy: Chances & Pitfalls (P. Armand, T. Lilge)
- Challenges in Older Lymphoma Patients (P. Bice, J. Friedberg)
- Minimum Residual Disease (W. Wilson, P. L. Zinzani)

Coffee Break

12:15 – 13:45 Biosimilar rituximab – a new treatment option by Sandra Germany (A. Engert)
- Biosimilar Development in Oncology (T. Dingemans)
- Clinical evidence for biosimilar rituximab (B. Glaß)
- Treatment of D20 positive, lymphocyte-predominant Hodgkin lymphoma (L. Warwick)

Coffee Break

14:00 – 15:30 Immunotherapy – Biomechanisms (A. Rosenwald, A. Younes)
- T-cells and PD1 Inhibition in cHL (M. Shipp)
- Immune- Evasion (M. K. Gandhi)

Oral Abstract Presentations

Coffee Break

16:00 – 17:30 Hodgkin lymphoma: How Can We Do Better? by Takeda (M. Hertzberg)
- Introduction (M. Hertzberg)
- Can we do better in front-line? Followed by iPad Audience Q&A with panel discussion (below: Q&A...) (A. Pavlovsky)
- Can we do better with salvage? (Q&A...) (C. H. Moskowitz)
- Assessing risk of failure throughout treatment (Q&A...) (M. H. Henes)
- Conclusion (M. Hertzberg)

Coffee Break

17:45 Opening Ceremony

19:45 Welcome Reception

Sunday (28.10.2018)

07:30 – 09:00 Interactive Case Discussion
(Faculty: M. Hertzberg, A. Lister / Presenters: D. A. Eichenauer, J. Rompeka-Janssens, O. Bolicchi, S. Bachmann)
- Stage IV NPHL (D. Eichenauer)
- 2nd Line cHL (J. Rompeka-Janssens)
- 3rd-line positive HL (O. Bolicchi)
- Progress on anti-PD1 mobil (S. Borchmann)

Coffee Break

09:15 – 10:15 Oncology meets Autoimmunity by Chugai (A. Engert)
- Autotransplant in systemic sclerosis (J. Henes)
- Autoimmunity in chronic GVHD (D. Wolf)

Oral Abstract Presentations

Coffee Break

10:30 – 12:00 Biology & Microenvironment (A. van den Berg, C. Steidl)
- Microenvironment (R. Küppers)
- Genotyping of cHL via Liquid Biopsy (O. Baiocchi)

Oral Abstract Presentations

Coffee Break

12:15 – 13:45 HL: Tailoring Sequencing and Treatment Targets by Takeda (P. Borchmann)
- Welcome and introduction (P. Borchmann)
- Considering consolidation after autologous stem cell transplantation (D. Molin)
- Relapse after autologous transplant: options and optimizing outcomes (A. Suendo)
- Considering patient factors: challenging cases and clinical management (A. J. Boucek)

Oral Abstract Presentations

Coffee Break

14:00 – 15:30 Early Stages (R. Hoppe, J. Raemaekers)
- Early-Stage Favorable HL: HO16 (A. Engert)
- BEND01: Randomized Phase II Trial (M. Anda)

Oral Abstract Presentations

Coffee Break

16:00 – 17:30 Focus on cHL: Current Insights and Future Perspectives by Bristol-Myers Squibb (P. Borchmann)
- The Evolving cHL Treatment Landscape (S. Ansell)
- Understanding the Unmet Need in cHL (P. Borchmann)
- Focus on Biomarkers: Biology as a Key Driver of Therapeutic Benefit (M. Shipp)
- Panel Discussion

Oral Abstract Presentations

Coffee Break

17:45 – 19:15 Survivorship & Patient Perspectives (E. van Leeuwen, A. Plate)
- What Patients Really Want: The Global Lymphoma Patient Survey (E. van Leeuwen)
- Cognitive Behavioral Therapy for Fatigue in HL (H. Knoop)
- Genetic Susceptibility (L. Morton)

Oral Abstract Presentations

Monday (29.10.2018)

07:30 – 09:00 Advanced Stages (V. Diehl, P. Johnson)
- CHECKLIST Update (J. Bradford)
- HD18 Update (P. Borchmann)
- LSA AH1011 Phase III Study (O. Casavvonas)

Oral Abstract Presentations

Coffee Break

09:15 – 10:15 CAR T Cell Therapies: Hype or Hope? by Celgene (H. Einsele)
- Preclinical Rationale for CAR T Cell Therapy (H. Abken)
- CD19 directed CAR T Cell Therapy in B-NHL (P. Borchmann)
- B-RMA-directed CAR T Cell Therapy in MM (H. Einsele)

Oral Abstract Presentations

Coffee Break

10:30 – 12:00 Pediatric HL (C. Mazzì-Kirihan, M. K. Kelly)
- PD-1 /−L1 Expression in Pediatric HL (S. Gattinolønos)
- Genotyping in Familial HL (L. P. Yang)
- Functional and Financial Outcomes after Treatment for Pediatric Hodgkin lymphoma (E. Persons)

Oral Abstract Presentations

Coffee Break

12:15 – 13:45 Checkpoint blockade in lymphomas (A. Engert)
- Basic in immunotherapy for lymphomas (D. Wolf)
- PD-1 blockade current and future aspects of cHL therapy (P. Borchmann)
- PD-1 blockade in NHLs (R. Hoppe)

Oral Abstract Presentations

Coffee Break

14:00 – 15:30 Immunotherapy – Clinical (P. Armand, M. Hutchings)
- Checkmate 205: Cohort D (S. Ansell)
- Toxicities from Checkpoint Inhibitor Therapy: Diagnosis, Management and Follow-up (P. Boelekelem)

Oral Abstract Presentations

Coffee Break

16:00 – 17:30 Relapsed/Refractory HL (C. H. Maskoskt, A. Suendo)
- BRAVE: Phase II Trial (A. Hagenbeck)
- Novel Agents in First Line Salvage (R. Advani)

Oral Abstract Presentations

Coffee Break

17:30 – 18:15 Closing Remarks

19:45 Welcome Reception